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Essentially every chemical reaction in the living 
cell is catalyzed, and most of the catalysts are 
protein enzymes. The catalytic efficiency of 
enzymes is remarkable: reactions can be 
accelerated by as much as 17 orders of 
magnitude over simple buffer catalysis. Many 
structural features contribute to the catalytic 
power of enzymes: holding reacting groups 
together in an orientation favorable for reaction 
(proximity); binding the transition state of the 
reaction more tightly than ground state 
complexes (transition state stabilization);  
acid-base catalysis, and so on.
Specific recognition of other molecules is 
central to protein function. The molecule that is 
bound (the ligand) can be as small as the 
oxygen molecule that coordinates to the heme 
group of myoglobin, or as large as the specific 
DNA sequence (called the TATA box) that is 
bound—and distorted—by the TATA binding 
protein. Specific binding is governed by shape 
complementarity and polar interactions such as 
hydrogen bonding.
Proteins are flexible molecules and their 
conformation can change in response to 
changes in pH or ligand binding. Such changes 
can be used as molecular switches to control 
cellular processes. One example, which is 
critically important for the molecular basis of 
many cancers, is the conformational change 
that occurs in the small GTPase Ras when GTP 
is hydrolyzed to GDP. The GTP-bound 
conformation is an "on" state that signals cell 
growth; the GDP-bound structure is the "off" 
signal.
Protein molecules serve as some of the major 
structural elements of living systems. This 
function depends on specific association of 
protein subunits with themselves as well as 
with other proteins, carbohydrates, and so on, 
enabling even complex systems like actin fibrils 
to assemble spontaneously. Structural proteins 
are also important sources of biomaterials, 
such as silk, collagen, and keratin.
Silk derives its strength and flexibility from its
structure: it is a giant stack of antiparallel beta sheets.
Its strength comes from the covalent and hydrogen
bonds within each sheet; the flexibility from the
van der Waals interactions that hold the
sheets together. (PDB 1slk)
"off" "on"
DNA replication is catalyzed by  
a specific polymerase
that copies the genetic material 
and edits the product for errors in 
the copy. (PDB 1pbx)
The TATA binding protein binds a specific 
DNA sequence and serves as the platform 
for a complex that initiates transcription of 
genetic information. (PDB 1tgh)
Myoglobin binds a molecule of oxygen
reversibly to the iron atom in its heme 
group (shown in grey with the iron in 
green). It stores oxygen for use in muscle 
tissues. (PDB 1a6k)
Replication of the AIDS virus HIV depends 
on the action of a protein-cleaving enzyme 
called HIV protease. This enzyme is the 
target for protease-inhibitor drugs (shown 
in grey). (PDB 1a8k)
Actin fibers are important for muscle contraction
and for the cytoskeleton. They are helical 
assemblies of actin and actin-associated proteins. 
(Courtesy of Ken Holmes)
The GDP-bound ("off"; PDB 1pll) state of Ras differs significantly from the GTP-bound ("on"; PDB 121p) state. 
This difference causes the two states to be recognized by different proteins in signal transduction pathways.
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Figure 1-1  Four examples of biochemical functions performed by proteins
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Proteins are the most versatile macromolecules of the cell
This book is concerned with the functions that proteins perform and how these are determined
by their structures. “Protein function” may mean the biochemical function of the molecule in
isolation, or the cellular function it performs as part of an assemblage or complex with other
molecules, or the phenotype it produces in the cell or organism.
Major examples of the biochemical functions of proteins include binding; catalysis; operating as
molecular switches; and serving as structural components of cells and organisms (Figure 1-1).
Proteins may bind to other macromolecules, such as DNA in the case of DNA polymerases or
gene regulatory proteins, or to proteins in the case of a transporter or a receptor that binds a 
signaling molecule. This function exploits the ability of proteins to present structurally and
chemically diverse surfaces that can interact with other molecules with high specificity. Catalysis
requires not only specific binding, to substrates and in some cases to regulatory molecules, but
also specific chemical reactivity. Regulated enzymes and switches, such as the signaling G pro-
teins (which are regulated enzymes that catalyze the hydrolysis of GTP), require large-scale 
conformational changes that depend on a delicate balance between structural stability and 
flexibility. Structural proteins may be as strong as silk or as tough and durable as keratin, the
protein component of hair, horn and feathers; or they may have complex dynamic properties
that depend on nucleotide hydrolysis, as in the case of actin and tubulin. This extraordinary
functional diversity and versatility of proteins derives from the chemical diversity of the side
chains of their constituent amino acids, the flexibility of the polypeptide chain, and the very
large number of ways in which polypeptide chains with different amino acid sequences can fold.
There are four levels of protein structure
Proteins are polymers of 20 different amino acids joined by peptide bonds. At physiological
temperatures in aqueous solution, the polypeptide chains of proteins fold into a form that in
most cases is globular (see Figure 1-2c). The sequence of the different amino acids in a 
protein, which is directly determined by the sequence of nucleotides in the gene encoding it,
is its primary structure (Figure 1-2a). This in turn determines how the protein folds into higher-
level structures. The secondary structure of the polypeptide chain can take the form either of
alpha helices or of beta strands, formed through regular hydrogen-bonding interactions
between N–H and C=O groups in the invariant parts of the amino acids in the polypeptide
backbone or main chain (Figure 1-2b). In the globular form of the protein, elements of either
alpha helix, or beta sheet, or both, as well as loops and links that have no secondary structure,
are folded into a tertiary structure (Figure 1-2c). Many proteins are formed by association of
the folded chains of more than one polypeptide; this constitutes the quaternary structure of a
protein (Figure 1-2d).
For a polypeptide to function as a protein, it must usually be able to form a stable tertiary
structure (or fold) under physiological conditions. On the other hand, the demands of protein
function require that the folded protein should not be too rigid. Presumably because of these
constraints, the number of folds adopted by proteins, though large, is limited. Whether the
limited number of folds reflects physical constraints on the number of stable folds, or simply
the expedience of divergent evolution from an existing stable fold, is not known, but it is a
matter of some practical importance: if there are many possible stable folds not represented in
nature, it should be possible to produce completely novel proteins for industrial and medical
applications.
Definitions
backbone: the regularly repeating part of a polymer. In
proteins it consists of the amide –N–H, alpha carbon –C
–H and the carbonyl –C=O groups of each amino acid.
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Figure 1-2 Levels of protein structure
illustrated by the catabolite activator protein
(a) The amino-acid sequence of a protein
(primary structure) contains all the information
needed to specify (b) the regular repeating
patterns of hydrogen-bonded backbone con-
formations (secondary structure) such as alpha
helices (red) and beta sheets (blue), as well as
(c) the way these elements pack together to form
the overall fold of the protein (tertiary structure)
(PDB 2cgp). (d) The relative arrangement of
two or more individual polypeptide chains is
called quaternary structure (PDB 1cgp).
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In a randomly coiled polypeptide chain the dipole moments of the individual backbone amide
groups point in random directions, but in an alpha helix the hydrogen-bonding pattern causes
all of the amides—and their dipole moments—to point in the same direction, roughly parallel
to the helical axis (Figure 1-13b). It is thought that, as a result, the individual peptide dipoles
in a helix add to make a macrodipole with the amino-terminal end of the helix polarized 
positively and the carboxy-terminal end polarized negatively. The magnitude of this helix
dipole should increase with increasing length of the helix, provided the cylinder remains
straight. Because favorable electrostatic interactions could be made between oppositely charged
species and the ends of the helix dipole, one might expect to find, at frequencies greater than
predicted by chance, negatively charged side chains and bound anions at the amino-terminal
ends of helices, and positively charged side chains and cations interacting with the carboxy-
terminal ends. Experimentally determined protein structures and studies of model peptides are
in accord with these predictions. Indeed, the helix dipole in some cases contributes significantly
to the binding of small charged molecules by proteins.
Alpha helices can be amphipathic, with one polar and one nonpolar
face
The alpha helix has 3.6 residues per turn, corresponding to a rotation of 100° per residue, so
that side chains project out from the helical axis at 100° intervals, as illustrated in Figure 1-15,
which shows the view down the helix axis. This periodicity means that, broadly speaking,
residues 3-4 amino acids apart in the linear sequence will project from the same face of an
alpha helix. In many alpha helices, polar and hydrophobic residues are distributed 3-4 residues
apart in the sequence, to produce an alpha helix with one hydrophilic face and one hydrophobic
face; such a helix is known as an amphipathic alpha helix, which can stabilize helix–helix 
packing. Helices with this character frequently occur on the surfaces of proteins, where their
polar faces are in contact with water, or at interfaces where polar residues interact with one
another: the distribution of polar and hydrophobic residues in a sequence is therefore useful in
positioning alpha helices in structure prediction, and in predicting their positions at interfaces.
Collagen and polyproline helices have special properties
Although the amino acid proline, which lacks an N–H group, is not frequently found in an
alpha helix, two interesting helical structures can be formed from sequences rich in proline
residues. The first is the collagen triple helix (Figure 1-16). Collagen is the main constituent of
the bones, tendons, ligaments and blood vessels of higher organisms and consists of a repeating
tripeptide in which every third residue is a glycine (GlyXY)n. X and Y are usually proline
residues, although lysine occurs sometimes. Many of the proline residues are hydroxylated
post-translationally. Each collagen strand forms a (left-handed) helical conformation and three
such strands coil around each other like those of a rope. The effect is to create a fibrous 
protein of great tensile strength. Collagen molecules more than 2 µm in length have been
observed. Denaturing the collagen triple helix by heating converts it to a disordered, 
dissociated, random mass that we call gelatin.
The second proline-rich conformation is that formed by polyproline sequences. When the
peptide bonds in a polyproline sequence are all trans it forms a left-handed helix with three
residues per turn. Such a conformation is easily recognized by other proteins, and helical
polyproline sequences often serve as docking sites for protein recognition modules, such as
SH3 domains in signal transduction pathways.
Figure 1-14 Table of helical parameters
Average conformational parameters of the most
commonly found helical secondary structure
elements.
Figure 1-16 The structure of collagen
Collagen is a three-chain fibrous protein in
which each chain winds round the others. 
The rise per residue is much larger than in 
an alpha helix.
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Figure 1-15 View along the axis of an
idealized alpha-helical polypeptide The view
is from the amino-terminal end. Side chains
project outward from the helical axis at 100º
intervals. Note that side chains four residues
apart in the sequence tend to cluster on the
same face of the helix, for shorter helices. For
long helices any such pattern would slowly coil
about the helix axis, so if two long helices had
a pattern of hydrophobic groups four residues
apart they would interact by forming a coiled
coil (see Figure 1-67). 
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Alpha helices are versatile cylindrical structures stabilized by a network
of backbone hydrogen bonds
Alpha helices are the commonest secondary structural elements in a folded polypeptide chain,
possibly because they are generated by local hydrogen bonding between C=O and N–H groups
close together in the sequence. In an alpha helix, the carbonyl oxygen atom of each residue (n)
accepts a hydrogen bond from the amide nitrogen four residues further along (n+4) in the
sequence (Figure 1-13c), so that all of the polar amide groups in the helix are hydrogen bonded
to one another except for the N–H group of the first residue in the helical segment (the amino-
terminal end) and the C=O group of the last one (the carboxy-terminal end). The result is a
cylindrical structure where the wall of the cylinder is formed by the hydrogen-bonded 
backbone, and the outside is studded with side chains. The protruding side chains determine
the interactions of the alpha helix both with other parts of a folded protein chain and with
other protein molecules.
The alpha helix is a compact structure, with approximate phi, psi values of –60° and –50°
respectively: the distance between successive residues along the helical axis (translational rise) is
only 1.5 Å (Figure 1-13a). It would take a helix 20 residues long to span a distance of 30 Å, the
thickness of the hydrophobic portion of a lipid bilayer (alpha helices are common in the trans-
membrane portions of proteins that span the lipid bilayer in cell membranes; see section 1-11).
Alpha helices can be right-handed (clockwise spiral staircase) or left-handed (counterclockwise),
but because all amino acids except glycine in proteins have the L-configuration, steric constraints
favor the right-handed helix, as the Ramachandran plot indicates (see Figure 1-11), and only a
turn or so of left-handed alpha helix has ever been observed in the structure of a real protein.
There appears to be no practical limit to the length of an alpha helix; helices hundreds of
Ångstroms long have been observed, such as in the keratin fibers that make up human hair.
There are variants of the alpha helix with slightly different helical parameters (Figure 1-14),
but they are much less common and are not very long because they are slightly less stable. 
Definitions
amphipathic alpha helix: an alpha helix with a
hydrophilic side and a hydrophobic side.
helical parameters: set of numerical values that define
the geometry of a helix. These include the number of
residues per turn, the translational rise per residue, and
the main-chain torsional angles.
helix dipole: the macrodipole that is thought to be
formed by the cumulative effect of the individual 
peptide dipoles in an alpha helix. The positive end of
the dipole is at the beginning (amino terminus) of the
helix; the negative end is at the carboxyl terminus of the
helical rod.
lipid bilayer: the structure of cellular membranes,
formed when two sheets of lipid molecules pack
against each other with their hydrophobic tails forming
the interior of the sandwich and their polar head-
groups covering the outside.
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Figure 1-13 The alpha helix The chain path
with average helical parameters is indicated
showing (a) the alpha carbons only, 
(b) the backbone fold with peptide dipoles and
(c) the full structure with backbone hydrogen
bonds in red. All three chains run from top to
bottom (that is, the amino-terminal end is at
the top). Note that the individual peptide
dipoles align to produce a macrodipole with its
positive end at the amino-terminal end of the
helix. Note also that the amino-terminal end
has unsatisfied hydrogen-bond donors (N–H
groups) whereas the carboxy-terminal end has
unsatisfied hydrogen-bond acceptors (C=O
groups). Usually a polar side chain is found at
the end of the helix, making hydrogen bonds to
these donors and acceptors; such a residue is
called a helix cap.
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the interactions of the alpha helix both with other parts of a folded protein chain and with
other protein molecules.
The alpha helix is a compact structure, with approximate phi, psi values of –60° and –50°
respectively: the distance between successive residues along the helical axis (translational rise) is
only 1.5 Å (Figure 1-13a). It would take a helix 20 residues long to span a distance of 30 Å, the
thickness of the hydro hobic portion of a lipid bilayer (alpha helices are common in the trans-
me brane portions of proteins that span the lipid bilayer in cell membranes; see section 1-11).
Alpha helices can be right-handed (clockwise spiral staircase) or left-handed (counterclockwise),
but because all amino aci s except glycine in proteins have the L-configuration, steric constraints
favor the right-handed helix, as the Ramachandran plot indicates (see Figure 1-11), and only a
turn or so of left-handed alpha helix has ever been observed in the structure of a real protein.
There appears to be no practical limit to the length of an alpha helix; helices hundreds of
Ångstroms long have been observed, such as in the keratin fibers that make up human hair.
There are variants of the al ha helix with slightly different helical parameters (Figure 1-14),
but they are much less common and are not very long because they are slightly less stable. 
Definitions
amphipathic alpha helix: an alpha helix with a
hydrophilic side and a hydrophobic side.
helical parameters: set of numerical values that define
the geometry of a helix. These include the number of
residues per turn, the translational rise per residue, and
the m i -chain torsional ngles.
helix dipole: the macrodipole that is thought to be
formed by the cumulative effect of the individual 
peptide dipoles in an alpha helix. The positive end of
the dipole is at the beginning (amino terminus) of the
h lix; the gative end is at the carbox  terminus of the
helical rod.
lipid bilayer: the structur  of cellular membranes,
formed when two sheets of lipid molecules pack
against each other with their hydrophobic tails forming
the interior of the sandwich and their polar head-
groups covering the outside.
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Figure 1-13 The alpha helix The chain path
with av rag  helical param ters s indicated
showing (a) the alpha carbons only, 
(b) the backbone fold with peptide dipoles and
(c) the full structure with backbone hydrogen
bonds in red. All three chains run from top to
bottom (that is, the amino-terminal end is at
th  top). Note that the individual peptide
dipoles align to produce a macrodipole with its
positive end at the amino-terminal end of the
helix. Note also that the amino-terminal end
has unsatisfied hydrogen-bond donors (N–H
groups) whereas the carboxy-terminal end has
unsatisfied hydrogen-bond acceptors (C=O
groups). Usually a polar side chain is found at
the end of the helix, making hydrogen bonds to
these donors and acceptors; such a residue is
called a helix cap.
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Chapter 1  From Sequence to Structure
Beta sheets are extended structures that sometimes form barrels
In contrast to the alpha helix, the beta pleated sheet, whose name derives from the corrugated
appearance of the extended polypeptide chain (Figure 1-17), involves hydrogen bonds between
backbone groups from residues distant from each other in the linear sequence. In beta sheets,
two or more strands that may be widely separated in the protein sequence are arranged side by
side, with hydrogen bonds between the strands (Figure 1-17). The strands can run in the same
direction (parallel beta sheet) or antiparallel to one another; mixed sheets with both parallel
and antiparallel strands are also possible (Figure 1-17). 
Nearly all polar amide groups are hydrogen bonded to one another in a beta-sheet structure,
except for the N–H and C=O groups on the outer sides of the two edge strands. Edge strands
may make hydrogen bonds in any of several ways. They may simply make hydrogen bonds to
water, if they are exposed to solvent; or they may pack against polar side chains in, for example,
a neighboring alpha helix; or they may make hydrogen bonds to an edge strand in another 
protein chain, forming an extended beta structure that spans more than one subunit and thereby
stabilizes quaternary structure (Figure 1-18). Or the sheet may curve round on itself to form a
barrel structure, with the two edge strands hydrogen bonding to one another to complete the
closed cylinder (Figure 1-19). Such beta barrels are a common feature of protein architecture.
Parallel sheets are always buried and small parallel sheets almost never occur. Antiparallel sheets
by contrast are frequently exposed to the aqueous environment on one face. These observations
suggest that antiparallel sheets are more stable, which is consistent with their hydrogen bonds
being more linear (see Figure 1-17). Silk, which is notoriously strong, is made up of stacks of
antiparallel beta sheets. Antiparallel sheets most commonly have beta turns connecting the
strands, although sometimes the strands may come from discontiguous regions of the linear
sequence, in which case the connections are more complex and may include segments of alpha
Definitions
antiparallel beta sheet: a beta sheet, often formed
from contiguous regions of the polypeptide chain, in
which each strand runs in the opposite direction from
its immediate neighbors.
beta barrel: a beta sheet in which the last strand is
hydrogen bonded to the first strand, forming a closed
cylinder.
mixed beta sheet: beta sheet containing both parallel
and antiparallel strands.
parallel beta sheet: a beta sheet, formed from non-
contiguous regions of the polypeptide chain, in which
every strand runs in the same direction.
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Figure 1-17  The structure of the beta sheet The left figure shows a mixed beta sheet, that is one containing both parallel and antiparallel segments. Note that
the hydrogen bonds are more linear in the antiparallel sheet. On the right are edge-on views of antiparallel (top) and parallel sheets (bottom). The corrugated
appearance gives rise to the name “pleated sheet” for these elements of secondary structure. Consecutive side chains, indicated here as numbered geometric
symbols, point from alternate faces of both types of sheet.
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Chapter 1  From Sequence to Structure
The folded structure of a protein is directly determined by its primary
structure
The three-dimensional or tertiary structure of a protein is determined by the sequence of
amino acids encoded by the gene that specifies the protein. Translation of the mRNA produces
a linear polymer of amino acids that usually folds spontaneously into a more compact, stable
structure. Sometimes folding is assisted by other proteins called chaperones, but most proteins
can be unfolded and refolded in dilute solution, demonstrating that the primary structure 
contains all the information necessary to specify the folded state. Protein folding can occur
quite rapidly, but there is evidence that one or more partially folded intermediate states often
exist, transiently, along the path to the final structure (Figure 1-22). The structures of these
intermediates are not as well characterized as the native structures, but have many of the 
secondary structure elements of the fully folded protein without the closely packed interior and
full complement of weak interactions that characterize what is termed the native state.
Competition between self-interactions and interactions with water 
drives protein folding
Consider a protein of arbitrary sequence emerging from the ribosome. If the chain is made
up of only polar and charged amino acids, nearly every chemical group in it can hydrogen
bond to water whether the chain is folded up or not, so there will be no driving force to form
a compact or regular structure. Many such sequences are known in nature, and, as expected,
they have no stable folded structure on their own in solution. The amino-acid sequences of
soluble proteins tend to be mixtures of polar and nonpolar residues, sometimes in patches,
but most often distributed along the chain with no discernible pattern. When such a
sequence is synthesized in water, it cannot remain as a fully extended polymer. True, the
polar and charged side chains, and the polar peptide groups, will be able to form hydrogen
bonds with water; but the nonpolar side chains cannot. Their physical presence will disrupt
the hydrogen-bonded structure of water without making any compensating hydrogen bonds
with the solvent. To minimize this effect on the water structure, these side chains will tend
to clump together the way oil droplets do when dispersed in water. This hydrophobic
effect—the clustering of hydrophobic side chains from diverse parts of the polypeptide
sequence—causes the polypeptide to become compact (Figure 1-23). From an energetic
point of view the compactness produces two favorable results: it minimizes the total
hydrophobic surface area in contact with water, and it brings the polarizable hydrophobic
groups close to each other, allowing van der Waals interactions between them. Polar side
chains do not need to be shielded from the solvent because they can hydrogen bond to water,
so they will tend to be distributed on the outside of this “oil drop” of hydrophobic residues. 
Definitions
chaperone: a protein that aids in the folding of another
protein by preventing the unwanted association of the
unfolded or partially folded forms of that protein with
itself or with others.
hydrophobic effect: the tendency of nonpolar groups
in water to self-associate and thereby minimize their
contact surface area with the polar solvent.
native state: the stably folded and functional form of a
biological macromolecule.
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Figure 1-22 Folding intermediates Structures of (a) denatured, (b) intermediate, (c) major transition
and (d) native states of barnase. Structures were determined from molecular dynamics calculations 
and NMR experiments, illustrating a possible folding pathway. Note that during folding, segments of
secondary structure form that do not completely coincide with their final positions in the sequence, 
and that the non-native states are considerably expanded and more flexible relative to the final folded
form. These characteristics appear to be common to most, if not all, protein-folding pathways. 
(Bond, C.J. et al.: Proc. Natl Acad. Sci. USA 1997, 94:13409–13413.)
(a)  denatured (b)  intermediate
(c)  major transition (d)  native
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Figure 1-21 An example of secondary
structure prediction An example of the
prediction of secondary structure from
sequence for a protein of unknown function
from the Enterococcus faecalis genome. 
Only the first 490 residues are shown. Eight
different statistical prediction schemes have
been applied to this sequence. What is 
striking is that all of the schemes agree on 
the approximate locations of the alpha helices
(h) and beta strands (e), but they disagree
considerably on the lengths and end positions
of these segments. Note also that the probable
positions of loops (indicated by a c) and turns
(indicated by a t) are very inconsistently
predicted. Such results are typical, but the
application of many methods is clearly more
informative than the use of a single one. The
bottom line shows the consensus prediction. 
                    10        20        30        40        50        60        70
                  |         |        |        |        |         |       |
UNK_7585500 MTKNESYSGIDYFRFIAALLIVAIHTSPLFSFSETGNFIFTRIVAPVAVPFFFMTSGFFLISRYTCNAEK
DPM         cccttttctccchhhhhhhheehecccccccccttcceeeeeeehceheceeehccceeeeeccccthhc
DSC         ccccccccccchhhhhhheeeeeecccccccccccccceeeeeccccccceeeccccceeeeccccchhh
GOR4        cccccccccchhhhhhhhhhhhhccccccccccccccceeeeecccccccccccccceeeeecccccccc
HNNC        cccccccchhhhhhhhhhhhhhhhhcccceeeccccceeeeeeeccccccheehccchhhhhccccchhh
PHD         cccccccccchhhhhhhhhhhhhhhcccceeeecccceeeeeeeeeeeeeeeeeccceeeeecccchhhh
Predator    ccccccccccchhhhhhhhhhhhhcccccccccccccceeeeeeeccceeeeecccceeeeecccchhhh
SIMPA96    ccccccccchhhhhhhhhhheeecccccccccccccceeeeeeccccccceeecccce eeeccccchhh
SOPM        hccttccttchhhhhhhhhheeeeccccceeecttcceeeeeeccccccceeeecttceeeehcccchhh
Sec.Cons.   cccccccccchhhhhhhhhh??h?ccccccccccccceeeeee?cccccceeecccceeeeeccccchhh
                    80        90       100       110       120       130       140
                  |        |         |       |        |       |         |
UNK_7585500 LGAFIKKTTLIYGVAILLYIPINVYNGYFKMDNLLPNIIKDIVFDGTLYHLWYLPASIIGAAIAWYLVKK
DPM       hchhhhhcceeeeeeeeeeececectcccchcccccc ec eeeccccccccccccceechhhhhheehh
DSC         hhhhhcccceeeeeeeeeeecccccccccccccccccccceeeccccccccccccccccccchhhhhhhh
GOR4        cccccccchhhhceeeeeecccceeccccccccccccceeeeeeccceeceeecccchhhhhhhhhhhhh
HNNC        hhhhhhhhhhhhhhhheeeecccecccceehchhhhhhhhhheecccheeheecchhhhhhhhhhhhhhh
PHD         hhhhhceeeeeecceeeeeeeeccccccccccccchhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhh
Predator    hhhhhcceeecccceeeeeeccccccccccccccccchhhhhcccceeeeeeeccchhhhhhhhhhhhhh
SIMPA96     hhhhhhhhhhhhceeeeeecccccccccccccccchhhhhhhcccccceeeeecchhhhhhhhhhhhhhh
SOPM        hhhhhhhheeeeeee eeeccccettcchhhhtcchhhhhhhe ttceee eecccchhhhh hhhhhhh
Sec.Cons.   hhhhh?h??eeeceeeeeeeccc?ccccccccccc??hhhhheeccc?eeeeeccc?hhhhhhhhhhhhh
                   150       160       170       180       190       200       210
                 |       |        |        |        |         |        |
UNK_7585500 VHYRKAFLIASILYIIGLFGDSYYGIVKSVSCLNVFYNLIFQLTDYTRNGIFFAPIFFVLGGYISDSPNR
DPM         ehhhhhhhhheeeeeeccctttccceeeeeeeeceeeceeehhccccccccehhceeeeecccctctttc
DSC         hccchhhhhhhheeeeecccccccceeecccccccccceeeeccccccccccccceeeeecccccccccc
GOR4        hhhhhhhhhhhhheeeecccccceeeeeeecccccccccceeccccccccceecceeeeccccccccccc
HNNC        hhhhhhhhhhhhhhhhhhcccccheheeeehhhhhhhhhhhhhhccccccheehhhhhhhcccccccccc
PHD         hhhhhhhhhhhhhhhhhhccccceeeeeeeccehhhhhhhhhhhhhhhcccceceeeeececeeeccccc
Predator   chhhhhhhhhhhhhhhhcc ccceee eccccchhhhhhhhhcccccccc eeeeeeeeecccccccccc
SIMPA96     hhhhhhhhhhhheeeecccccchhhhhhhhhhhhhhhhhhhhcccccccceeeeeeeeeecccccccccc
SOPM       cchtthhhhhhhhheeeecccchhhh hhhhhhhhhhhhheeehcccttteeecceeeeetcccc cttt
Sec.Cons.   hhhhhhhhhhhhh?ee?cccccc?eeeeeecc?hhhhhhh?hccccccccceecceeeeecccccccccc
                   220       230       240       250       260       270       280
                     |         |         |         |         |         |         |
UNK_7585500 YRKKNYIRIYSLFCLMFGKTLTLQHFDIQKHDSMYVLLLPSVWCLFNLLLHFRGKRRTGLRTISLDQLYH
DPM         cctccceeeeeeeehhhccchchhhhhhhccccheeeeecceeeehhhhhhhhtcctcccccechccccc
DSC         ccccccceeeeeeeccccccccccccccccccceeeeecccchhhhhhheecccccccccceeecccccc
GOR4        ccccceeeeeeeeeecccccceecceeeecccceeeeeecccccccchhhhccccccccceeecccceec
HNNC      c hchheeehhhhhhhcccccee eeeeccccce eeehhhhhhhhhhhehcccccccceeeeee eecc
PHD         ccccceeeeeecceeccccceeeeccccccccceeeeeeccchhhhhhhhhhcccecccccceeccccce
Predat r    ccccc eee ehhhhhhccee ecccccccc cce ee ccchh hhhhhhcccccccceeeeeeccccc
SIMPA96     cccccceeeeeeeeeeccceeeeeccccccccceeeeeeccchhhhheeeeecccccccceeeehhhhcc
SOPM      cccccheeeeee eeett t eeeeeeccttcceeeeecchhhhhh hhheettcccccceeeeehhhhh
Sec.Cons.   ccccc?eeeeeeeee?cccceeeeccccccccceeeeeeccchhhhhhhhhccccccccceeee?ccccc
                   290       300       310       320       330       340       350
                     |         |         |         |         |         |         |
UNK_7585500 SSVYDCCNTIVCAELLHLQSLLVENSLVHYIAVCFASVVLAVVITALLSSLKPKKAKHTADTDRAYLEIN
DPM         ccecccccceehhhhhhhhhhhhhcceeeeeheeeheeeeeeeeehhhccctccchchchccchhhhhhc
DSC         ccccccccceeehhhhhhhhhhhcccccceeeeecccceeeeeeeecccccccccccccccchhhhheee
GOR4        cceecccceeeecchhhhhhhhhhcceeeeeeecccccchhhhhhhhhhhcchhhhhcccccchhhhhhh
HNNC        ccchhhhhhheehhhhhhhhhehcchhhhhhhhhhhhhhhhhhhhhhhhhhcccccccccchhhhhhheh
PHD         cccchhhhhhhhhhhhhhhhhhhhhheeeeeeeeeeeeehhhhhhhhhhhhcccccccccchhhhhhhhh
Predator    cccccccccchhhhhhhhhhhhcccccceeehhhhhhhhhhhhhhhhccccccccccccccccceeeeec
SIMPA96    cccccccceeehhhhhhhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhc c cccccccchhhhhhhc
SOPM        hhhhhtthhhhhhhhhhhhhhhhhtthhheeehhhhhhhhhhhhhhhhhtccttccccccccchhheehh
Sec.Cons.   cccccccc?eehhhhhhhhhhhh?cc??eee??hhhhhhhhhhhhhhhhhcccccccccccc?hhhhhhh
                   360       370       380       390       400       410       420
                     |         |         |         |         |         |         |
UNK_7585500 LNNLEHNVNTLQKAMSPKCELMAVVKAEAYGHGMYEVTTYFEPIGVFYLAVATIDEGIRLRKYGIFSEIL
DPM         cccccctecchhhhhttchhhhhhhhhhhtcccccheeccccccceeehhehhechchhhhhcceeehee
DSC         hhhhhhhhhhhhhcccccceeeeeeeecccccccchhhhhhhhcccchheehhhhhhhhhhhhhccccee
GOR4        hhhhhhchhhhhhccccchhhhhhhhhhhcccceeeeeeeccccceeeeehhhhhhhhhhhhcccceeee
HNNC        ccccccchhhhhhcccchhhhhhhhhhhhhcccceeeeeeccchhhhhhhhhhhhhhhhhchccecheee
PHD         hhhhhhhhhhhhhhccccceeeeeeeecccccchhhhhhhhhhhhhhhheccchhhhhhhhhhhccccee
Predator    cccccccccccccccccchhhhhhhhhhhcccceeeeeecccccchhhhhhhcccccccccccccceeee
SIMPA96     hhhhhhhhhhhhhhccchhhhhhhhhhccccccceeeeecccccceeeeehhhhccchhhhhccccceee
SOPM        hhhhhhhhhhhhhhhccthhhhhhhhhhhtttthheeeeeccctteeeeeehhhhttceechtteehhee
Sec.Cons.   hhhhhhhhhhhhh?cccchhhhhhhhhhhccccceeeee?cccccee?hehhhhhhhhhhhhcccc?eee
                   430       440       450       460       470       480       490
                     |         |         |         |         |         |         |
UNK_7585500 ILGYTSPSRAKELCKFELTQTLIDYRYLLLLNKQGYDIKAHIKIDTGMHRLGFSTEDKDKILAAFFLKHI
DPM         eecccctcchhhhhhhhhhhceecchehhhhttccccchhhehccccccccccttctcchhhhhhhhhhe
DSC         eecccccchhhhhcceeeccccccchhhhhhhhhhccceeeeeeccccceeeecchhhhhhhhhhhcchh
GOR4        eecccccchhhhhhhhcccchhhhhhhhhhhcccccceeeeeccccceeeecccchhhhhhhhhhhhhhh
HNNC        eeecccccchhhhhhhhhhhhhhhhhhhhhhhcccccheeeeeeccccccecccccchhhhhhhhhhhhh
PHD         eeecccchhhhhhhhhhhheeccchhhhhhhhhhhhheeeeeeeccccccccccchhhhhhhhhhhhhce
Predator    eecccccchhhhhhhhhhhhhhchhhhhhhhhcccccceeeeecccccccccccccccchhhhhhhhhhh
SIMPA96     eeccccchhhhhhhhhhhhhhhhhhhheeeecccccccceeeeecccceeeccccchhhhhhhhhhhhhc
SOPM        eeeccccchhhhhhhhhhhhhhhhhhheeeettttcceeeeeeecttceeetccccchhhhhhhhhhhhc
Sec.Cons.   eecccccchhhhhhhhhhhhhhhhhhhhhhhhcccccceeeeeeccccc?eccccchhhhhhhhhhhhhh
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that shape the energy landscape in favour of functional
folded proteins and the influence of extrinsic, cellular fac-
tors in shaping the landscape will be discussed, highlighting
in particular how evolution has solved the ‘protein folding
problem’ by establishing amino acid sequences that fold
into stable proteins with desired functions whilst avoiding
non-native, non-functional conformers. Finally, we con-
clude by pointing out the challenges that lie ahead in our
quest to understand protein folding energy landscapes in
atomistic detail and how we might hope to utilise this
knowledge to control the partitioning between folding
and aggregation in the future.
Towards the description of protein conformational ensembles
The folding side of the protein energy landscape
The fact that protein folding must occur within a biolog-
ically feasible timescale excludes the possibility of a ran-
dom-search mechanism for protein folding [1]. Therefore,
and as a general principle, kinetic pathways lay the founda-
tion to an ordered protein folding reaction. Although the
complete folding trajectory of only very simple proteins
has been determined at atomic-level resolution to date
[2], biophysical and theoretical experiments picture protein
folding, in general, as a sequential and highly cooperative
reaction [3]. To envision the conformational space avail-
able to each individual polypeptide sequence under a given
condition, the concept of energy landscapes was introduced
[4,5]. This theoretical formalism describes the progression
of unfolded polypeptide chains along an energy landscape
towards the compact native structure (Fig. 1). For small
proteins this landscape appears to be funnel-like and repre-
sents the evolutionary selection of polypeptide sequences
able to fold rapidly and reliably towards a unique native
state [6]. On the other hand, larger polypeptide sequences
have rougher energy landscapes, allowing the population
of partially folded species that may be on- or off-pathway
to the native fold [7,8]. Characterising the multitude of con-
formational states populated on this energy landscape is
not only crucial for developing an understanding of the
determinants of protein folding and aspects of protein
function, but it also contains crucial clues about side-reac-
tions such as protein aggregation [9,10]. Such a character-
isation involves describing the structural, kinetic and
thermodynamic properties of all conformations accessible
to a given polypeptide sequence. Obtaining this description
has proved to be immensely challenging, however, as tech-
niques able to resolve and structurally characterise these
rapidly interconverting species needed to be developed, as
well as the theoretical framework to interpret them. None-
theless, using an array of ingenious experiments and by
combining these with simulations and new theories,
detailed insights into at least the most highly populated
conformational ensembles on the protein folding landscape
and the transition state barriers that separate them have
emerged over the recent years.
Unfolded states
Over the last decade enormous progress has been made
in describing the conformation of unfolded states. These
Fig. 1. Illustration of a combined energy landscape for protein folding and aggregation. (a) The surface illustrates the roughness of the protein energy
landscape, showing the multitude of conformational states available to a polypeptide chain. While rather simple folding funnels (light grey) can describe
the conformational search of a single polypeptide chain to a functional monomer, intermolecular protein association dramatically increases ruggedness
(dark grey). (b) Proposed pathways linking the conformational states shown in (a) populated on the combined folding and aggregation energy landscape.
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entire fibril (Fig. 4E). The molecular details that lead to this
regular spacing are currently unclear. However, it has been
reported that residue 4 can form specific intermolecular cross-
links with methionine 35 in A!(1–42) fibrils (18), suggesting that
the structurally heterogeneous peptide segment 1–16 (see Fig. 1
E and F) is involved in interprotofilament binding and
organization.
Fibril extension most likely occurs at the tip of the protofila-
ments. The domain swapping-type interactions between A!(1–
42) molecules imply the presence of distinct surfaces at the
opposing ends: In contrast to the even end (Fig. 10, which is
published as supporting information on the PNAS web site), a
hydrophobic cleft is formed by strand !1 and strand !2 of the
template at the odd end of the protofilament (Fig. 4C). An
incoming A! monomer could initially bind by means of the
contiguous hydrophobic stretch of residues 17–21. This complex
could be further stabilized by the formation of the intermolec-
ular salt-bridge and backbone H bonds. However, the newly
added monomer could still dissociate, because the !2-strand has
substantially fewer interactions with the template than !1.
Hence, the last added A! monomer would be stabilized perma-
nently only by the addition of the next monomer, suggesting a
sequence-selective, cooperative mechanism of A! fibril exten-
sion that follows first-order kinetics. Recently, apparent unidi-
rectional A!(1–40) fibril growth with a constant slow rate was
directly observed (27). Therefore, key experimental observa-
tions on fibril growth are in good agreement with the molecular
mechanism suggested here, based on the structure of the A!(1–
42) protofilament. It appears evident that this mechanism also
provides a rationale for the activity of A! peptide analog
inhibitors comprising the A! peptide segment of residues 17–21
(24, 28). They would presumably bind to the hydrophobic stretch
of residues 17–21 (Fig. 4C), thereby blocking this site and
preventing incoming A!molecules from extending the fibril (see
above and Fig. 6).
Biological Activity of A!. During the presented structural investi-
gation, morphological variants of A!(1–42) aggregates were
obtained that all share a virtually identical amino acid sequence.
Because all deviations fromWTmorphology can be rationalized
based on the presented structure, this set of variants appeared
suitable for a structure–function study of A!(1–42). The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide-
formazan assay (MTT assay) is a widely used assay of cell
viability and cellular response to A!. To determine the cyto-
toxicity of the 35LA!(1–42) variants, we used this assay in the
CNS cell line B12, which is susceptible to A! toxicity (29) (see
also Supporting Text). Table 2, which is published as supporting
information on the PNAS web site, summarizes the results: All
variants displayed a detectable neurotoxic response. With the
exception of the variant K28D, themost toxic peptides all formed
fibrils (Fig. 2 B–J and Table 1) and displayed toxicity similar to
synthetic A!(25–35), which was used as a reference. A lower but
still significant toxicity was observed for the variants F19G and
Fig. 4. The 3D structure of a 35MoxA!(1–42) fibril. (A and B) Ribbon diagrams of the core structure of residues 17–42 illustrating the intermolecular nature of
the inter-!-strand interactions. Individual molecules are colored. For example, the monomer at the odd end is shown in cyan. The !-strands are indicated by
arrows, nonregular secondary structure is indicated by spline curves through the C" atom coordinates of the corresponding residues, and the bonds of side chains
that constitute the core of the protofilament are shown. In B, the intermolecular salt bridge between residues D23 and K28 is indicated by dotted lines, and the
two salt bridges formed by the central A!(1–42) molecule are highlighted by rectangles. (C) van der Waals contact surface polarity and ribbon diagram at the
odd end of the 35MoxA!(1–42) protofilament comprising residues 17–42. The !-sheets are indicated by cyan arrows, and nonregular secondary structure is
indicated by gray spline curves. The hydrophobic, polar, negatively charged, and positively charged amino acid side chains are shown in yellow, green, red, and
blue, respectively. Positively and negatively charged surface patches are shown in blue and red, respectively, and all others are shown in white. The direction
of the fibril axis is indicated by an arrow pointing from even to odd. (D) (Upper) Simulation of a 35MoxA!(1–42) fibril that consists of four protofilaments colored
individually. Lower shows the same fibril in a noisy gray-scale image, which has been blurred corresponding to a resolution of 2 nm. In Right, a !5-magnified
cross section perpendicular to the fibril axis is shown, using the same color code. Dimensions are indicated. Tomatch the experimental twist of the protofilament
of the fibril shown in E, a twist angle of 0.45° per molecule was used. (E) Two examples of cryoelectron micrographs of single 35MoxA!(1–42) fibrils. (Scale bar,
50 nm.)
17346 ! www.pnas.org"cgi"doi"10.1073"pnas.0506723102 Lu¨hrs et al.
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Table 1 Human diseases associated with formation of extracellular amyloid deposits or intracellular inclusions with
amyloid-like characteristics
Disease
Aggregating protein or
peptide
Number of
residuesa
Native structure of protein or
peptideb
Neurodegenerative diseases
Alzheimer’s diseasec Amyloid β peptide 40 or 42f Natively unfolded
Spongiform encephalopathiesc,e Prion protein or
fragments thereof
253 Natively unfolded (residues 1–120)
and α-helical (residues 121–230)
Parkinson’s diseasec α-Synuclein 140 Natively unfolded
Dementia with Lewy bodiesc α-Synuclein 140 Natively unfolded
Frontotemporal dementia with
Parkinsonismc
Tau 352–441f Natively unfolded
Amyotrophic lateral sclerosisc Superoxide dismutase 1 153 All-β, Ig like
Huntington’s diseased Huntingtin with polyQ
expansion
3144g Largely natively unfolded
Spinocerebellar ataxiasd Ataxins with polyQ
expansion
816g,h All-β, AXH domain (residues
562–694); the rest are unknown
Spinocerebellar ataxia 17d TATA box-binding
protein with polyQ
expansion
339g α+β, TBP like (residues 159–339);
unknown (residues 1–158)
Spinal and bulbar muscular atrophyd Androgen receptor with
polyQ expansion
919g All-α, nuclear receptor
ligand-binding domain (residues
669–919); the rest are unknown
Hereditary
dentatorubral-pallidoluysian atrophyd
Atrophin-1 with polyQ
expansion
1185g Unknown
Familial British dementiad ABri 23 Natively unfolded
Familial Danish dementiad ADan 23 Natively unfolded
Nonneuropathic systemic amyloidoses
AL amyloidosisc Immunoglobulin light
chains or fragments
∼90f All-β, Ig like
AA amyloidosisc Fragments of serum
amyloid A protein
76–104f All-α, unknown fold
Familial Mediterranean feverc Fragments of serum
amyloid A protein
76–104f All-α, unknown fold
Senile systemic amyloidosisc Wild-type transthyretin 127 All-β, prealbumin like
Familial amyloidotic polyneuropathyd Mutants of transthyretin 127 All-β, prealbumin like
Hemodialysis-related amyloidosisc β2-microglobulin 99 All-β, Ig like
ApoAI amyloidosisd N-terminal fragments of
apolipoprotein AI
80–93f Natively unfolded
ApoAII amyloidosisd N-terminal fragment of
apolipoprotein AII
98i Unknown
ApoAIV amyloidosisc N-terminal fragment of
apolipoprotein AIV
∼70 Unknown
Finnish hereditary amyloidosisd Fragments of gelsolin
mutants
71 Natively unfolded
Lysozyme amyloidosisd Mutants of lysozyme 130 α+β, lysozyme fold
Fibrinogen amyloidosisd Variants of fibrinogen
α-chain
27–81f Unknown
Icelandic hereditary cerebral amyloid
angiopathyd
Mutant of cystatin C 120 α+β, cystatin like
(Continued )
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ApoAII amyloidosisd N-terminal fragment of
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Table 1 (Continued )
i
i
onneuropathic localized diseases
Type II diabetesc in, also called islet
amyloid polypeptide
(IAPP)
37 l
Medullary carcinoma of the thyroidc Calcitonin 32 i l l
Atrial amyloidosisc Atrial natriuretic factor 28 i l f l
Heredi ary cerebral haemorrhage with
amyloidosi d
M tants of amyloid β
peptide
40 or 2f i l f l
Pituita y rolactinoma Prolactin 99 ll α, 4-helical cytokines
Injection-localized amyloidosisc Insuli 2 + 30j All-α, insulin like
Aortic medial amyloidosisc Medi 50k Unknown
Hereditary lattice corneal dystrophyd M inly C-terminal
fragments of
kerato-epithelin
50–200f Unknown
Corneal amylodosis associated with
trichiasisc
Lactoferrin 692 α+β, periplasmic-binding protein
like II
Cataractc γ-Crystallins Variable ll-β, γ-crystallin like
Calcifying epithelial odontogenic
tumorsc
Unknown ∼46 Unk own
Pulmonary alveolar proteinosisd Lung surfactant rotein C 35
Inclusion-body myositisc Amyloid β peptide 40 or 42f Natively unfolded
Cutaneous lichen a yloidosisc Keratins Variable Unknown
aData refer to t e numb r of residues of the processed polypeptide chains that deposit into aggregates, not of the precursor proteins.
bAccording to Structural Classification Of Proteins (SCOP), these are the structural class and fold of the native states of the processed peptides or
proteins that deposit into aggregates prior to aggregation.
cPredominantly sporadic, although in some cases hereditary forms associated with specific mutations are well documented.
dPredominantly hereditary, although in some cases sporadic forms are documented.
eFive percent of the cases are transmitted (e.g., iatrogenic).
fFragments of various lengths are generated and have been reported to be present in ex vivo fibrils.
gLengths shown refer to the normal sequences with nonpathogenic traits of polyQ.
hLength shown is for ataxin-1.
iThe pathogenic mutation converts the stop codon into a Gly codon, extending the 77-residue protein by 21 additional residues.
jHuman insulin consists of two cha ns (A and B, with 21 and 30 residues, respectively) covalently linked by disulfide bridges.
kMedin is the 245–294 fragment of human lactadherin.
cross-polarized light has recently b en ques-
tioned (16, 17).
The proteins found as intractable aggre-
gates in pathological conditions do not share
any obvious sequence identity or structural
homology to each other. Considerable het-
erogeneity also exists as to secondary structure
composition or chain length (Table 1). Inter-
estingly, some amyloid deposits in vivo and
fibrils generated in vitro have both been found
to include higher- rder assemblies, including
highly organized species knownas spherulites,
which can be identified from a characteris-
tic Maltese cross pattern when observed un-
der cross-polarized light (18, 19). Such species
are also observed in preparations of synthetic
polymers, such as polyethylene, a finding
consistent with the idea that amyloid fibrils
have features analogous to those of classical
polymers.
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a
c
b
α-Synuclein
Vesicle membrane
Formation of
α-helices
Dimerization
with β-sheet
formation
Dimerization
with β-sheet
formation
Oligomerization
Oligomerization
Figure 4
α-Synuclein (α-syn) requires lipid interactions to form dimers, oligomers, and mature amyloid fibrils. (a) In
solution, α-syn is natively unfolded. (b) In the presence of vesicle membranes containing anionic
phospholipids, the N terminus of α-syn forms two α-helices that allow it to associate with the surface of the
membrane. (c) Stabilization of α-syn’s membrane interactions (through the A53T or E46K mutations) or
increased α-syn concentration (through genetic multiplication) facilitates the formation of α-syn dimers on
the membrane surface or in the cytoplasm. Through dimerization, α-syn adopts a β-sheet secondary
structure that, through association with α-syn monomers or other dimers, leads to oligomer formation.
These oligomers seed fibril formation and deposit as amyloid within Lewy bodies and Lewy neurites.
accumulation (Figure 5b). The increased lo-
cal concentration of α-syn on these stalled
vesicles favors the nucleation of higher-
order oligomeric species (Figure 4c). These
oligomeric species could then be free to dis-
perse and interfere with trafficking between
other compartments within the neuron. Ulti-
mately, these oligomers may come together to
form the amyloid fibrils (Figure 4c) found in
LNs and LBs, which in fact may simply be an
inert epiphenomenon.
CONSEQUENCES OF
α-SYNUCLEIN LIPID AND
MEMBRANE INTERACTIONS
Howmight α-syn’s abnormal lipid interactions
mediate the diverse pathological features seen
in PD? Abnormal interactions between α-syn
and vesicles likely are initiated at the synapse,
where α-syn is normally located (Figure 6).
However, under pathological conditions, α-
syn may also interact with and disrupt vesi-
cle trafficking in other compartments where it
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MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVH
GVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQL
G---KNEEGAP---QEGILEDMPVDPDNEAYEM-PSEEGYQDYEPEA
MDVFMKGLSMAKEGVVAAAEKTKQGVTEAAEKTKEGVLYVGSKTREGVVQ
GVASVAEKTKEQASHLGGAVFSG-----------AGNIAAATGLVKREEF
PTDLKPEEVAQEAAEEPLIEPL-MEPEGESYEDPPQEE-YQEYEPEA
α-Syn
β-Syn
Δ71–82
A30P E46K
A53T
a
b
Hydrophobic
domain 
Polar domain 
M
S E
K
K
G
GA
V
K
L
Figure 2
α-Synuclein (α-syn) and β-syn (red and blue, respectively) are highly
homologous. (a) The highly conserved, imperfect repeats that form A2-type
amphipathic α-helices are in bold. The hydrophobic core (!71–82), which is
required for α-syn fibrillization in vitro and toxicity in vivo, is indicated by the
horizontal line. This hydrophobic domain is absent in β-syn. Arrows identify
the location of the point mutations associated with familial Parkinson’s disease.
(b) An axial view of α-syn residues when displayed on an Edmundson helix
wheel. Polar residues (i.e., S, E, and K) face the hydrophilic environment of the
cytosol, whereas hydrophophic residues are buried in the acyl chains of the
phospholipid bilayer. Positively charged lysine residues (K) separate the polar
and hydrophobic domains and interact directly with the anionic surface of the
phospholipid bilayer.
Despite the significant homology between
α- and β-syn, only α-syn forms detergent-
resistant amyloid deposits in PD, DLB, and
MSA. The critical difference between α-
and β-syn is the presence of a highly hy-
drophobic 12–amino acid stretch at its cen-
ter (71-VTGVTAVAQKTV-82) (Figure 2a;
Giasson et al. 2001).This domain is required for
the oligomerization and fibrilization of α-syn.
Moreover, deletionor disruptionof this domain
through the addition of a charged amino acid
abrogates α-syn’s ability to form amyloid fib-
rils (Giasson et al. 2001). It is the amyloid form
of α-syn that aggregates within neurons as LBs
and LNs and within oligodendrocytes as GCIs.
However, the body of evidence suggests that
these α-syn amyloids are not required for toxi-
city (see below). Instead, early misfolded forms
of α-syn, possibly dimers or small oligomers,
are proposed to be the toxic species in the synu-
cleinopathies.
The disease-associated mutations alter α-
syn’s structure in different ways. The A53T
mutation effectively expands the hydrophobic
domain fro 11 amino acids to ∼30 amino
acids by destabilizing the α-helical domain be-
tween residues 51 and 66 (Biere et al. 2000).
This expanded hydrophobic core confers gain-
of-function toxicity (Biere et al. 2000) by fa-
cilitating the protein’s ability to adopt the
β-sheet structure required for the formation of
oligomeric species (Conway et al. 1998,Giasson
et al. 1999, Hashimoto et al. 1998). The A30P
mutation disrupts the first α-helical domain
of α-syn and reduces its affinity for phospho-
lipids. This mutation also reduces amyloid for-
mation in vitro (Yonetani et al. 2009), perhaps
by shifting the equilibrium tomore stable, solu-
ble toxic oligomers. Finally, theE46Kmutation
is thought to elicit toxicity by altering α-syn’s
interactions with anionic phosopholipids, ex-
posing the hydrophobic surfaces for potential
intermolecular interactions (Rospigliosi et al.
2009). These increased intermolecular interac-
tions would accelerate dimer formation and the
subsequent generation of toxic oligomers.
α-SYNUCLEIN INTERACTSWITH
LIPIDS AND MEMBRANES
Although the exact function of α-syn is still un-
clear, substantial evidence now exists to sug-
gest that α-syn interacts directly with lipids
and membranes both physiologically as well
as pathologically. In solution, α-syn does
not adopt a consistent secondary structure
216 Auluck · Caraveo · Lindquist
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a significant decrease in chaperone concentration could
be responsible for cell death71. Regardless of which
hypothesis proves to be true (FIG. 3), these Drosophila
studies indicate that increasing chaperone activity in 
the brain could be a useful therapeutic approach to
synucleinopathies such as PD.
Drosophila that overexpress !-synuclein have also
been used to investigate the function of parkin.Yang and
colleagues co-expressed human parkin and !-synuclein
in Drosophila. The presence of parkin protected about
50% of DA neurons from death when compared to 
flies that expressed only !-synuclein. In addition, flies
expressing parkin showed no !-synuclein granular
inclusions, and reduced ubiquitin in DA neurons72.
These results indicate that parkin might reduce the for-
mation of protein accumulations in synucleinopathies
and is neuroprotective, at least in this Drosophila model.
Deletion of parkin in Drosophila reduced the lifespan
of the flies, induced sterility in males, and decreased
flight and climbing ability73. The defects in locomotor
behaviour were not due to degeneration of the DA 
system,but to abnormal muscle fibre structure. In fact,
DA neurons of parkin-null Drosophi la were mostly 
normal in number and TH intensity, although cell bodies
in the dorsomedial DA cluster were shrunken and had
decreased neuritic TH immunostaining.
The Drosophila parkin knockout did not reproduce
the DA cell loss that occurs in humans with ARJP, who
lack parkin.One possible explanation for the lack of DA
cell loss in the parkin-null flies is that Drosophila do not
have the glycosylated 22-kDa form of !-synuclein,
which is one of the substrates for parkin6. This soluble
!-synuclein species accumulates in ARJP and might be
toxic to nigral neurons. As the flies cannot accumulate
this protein,deletion of parkin would not be expected
to be deleterious to DA neurons in Drosophila.
The Drosophilamodel has strengths and limitations.
Its limitations are the lack of glycosylated !-synuclein,
and that the nervous system of the fly is relatively simple
so that only a narrow range of locomotor behaviours
can be tested. The value of this model is that Drosophila
genes are highly homologous to their human counter-
parts, and entire genetic pathways have been conserved
during evolution74. Further, the mechanisms of
neurodegeneration in flies and humans are similar.
Specifically,high concentrations of !-synuclein in the
brain lead to the loss of DA neurons, the formation 
of inclusions with the morphology of Lewy bodies 
and deficient motor output, which are reversible 
following treatment with anti-parkinsonian medica-
tions.Despite the fact that Drosophi la normally lack 
!-synuclein, it is interesting that processing of the 
protein seems to be similar between this model 
and humans, and that the specificity of toxicity to DA
neurons is maintained.
Transgenic mice. Transgenic rodent models have also
been used in an attempt to elucidate the pathogenesis of
the synucleinopathies. The most numerous of these
models are !-synuclein transgenic mice created using
various gene promoters.
flies contained more phosphorylated !-synuclein than
other transgenic animals66. This could be explained by
the more rapid formation of fibrils by the A53T mutant
protein24, which would make more fibrils available 
for phosphorylation. The finding that chaperones —
molecules that aid protein folding and the formation of
correct tertiary structure — can prevent protein 
misfolding in Drosophi la models of polyglutamate 
disease70 has generated interest in these proteins as
potential neuroprotective agents. In support of this idea,
co-expression of human heat-shock protein 70 (Hsp70)
alleviated the toxicity of !-synuclein in transgenic flies64.
Conversely, when the constitutive Drosophi la Hsp70
chaperone Hsc4 was rendered defective in flies over-
expressing !-synuclein, the flies had 50% fewer DA 
neurons at birth and accelerated !-synuclein-induced
DA cell loss in adulthood64. Increasing chaperone 
activity by geldanamycin treatment delayed DA neuron
degeneration in wild-type and mutant (A30P and
A53T) !-synuclein transgenic flies64.
There are several mechanisms by which chaperone
molecules could mitigate the deleterious effects of
!-synuclein. First, although they do not affect the 
morphology of the inclusion bodies, chaperones might
reduce the toxicity of potentially toxic protofibrils or
oligomers by altering their protein structures.
Additionally,by modulating the structure of !-synuclein
proteins, chaperones might inhibit their interaction
with other neurotoxic proteins that can activate cell
death pathways71. Alternatively, chaperone molecules
could be sequestered in Lewy bodies and Lewy neurites,
leading to chaperone depletion in the cells.As chaperones
direct the folding and function ofmany cellular proteins,
!-Synuclein
protofibrils
(oligomers)
Lewy bodies
Chaperone
Non-toxic !-synuclein
conformations
Interaction with potential
neurotoxic proteins
Chaperone
depletion
3
1
2
2
3
Dopamine neuron cell death
Motor impairment
Figure 3 | Relationship between chaperone molecules and !-synuclein toxicity. It has
been proposed that chaperones might alter the conformation of highly toxic protofibrils or
oligomers — the intermediates of fibril formation — and reduce their neurotoxicity through
changes in protein structure (1). By modulating the structure of !-synuclein, chaperones inhibit
their interaction with other neurotoxic proteins that would activate cell death pathways (2). In the
synucleinopathies, chaperone molecules become sequestered in Lewy bodies and Lewy neurites,
leading to chaperone depletion, which might be directly responsible for cell death (3) (REF. 71).
736 | SEPTEMBER 2003 | VOLUME 4  www.nature.com/reviews/neuro
R E V I EW S
models are advantageous because they uniformly show
DA neurodegeneration and a pattern ofmotor impair-
ment that is characteristic of PD, whereas the genetic
models exhibit significant variability in these parameters.
The rotenone-treated rat is the only model that 
replicates all of the key features of synucleinopathies
such as PD. However, expression of the syndrome is 
variable,occurring in fewer than 50% of animals treated,
and maintenance of the animals is labour-intensive.
!-Synuclein transgenic flies are also excellent genetic
models of PD; their disadvantages are the limited range
of locomotor behaviour that can be tested in flies, and
the fact that flies represent a simpler system than rodents
and primates.
None of the transgenic mice models show DA cell
death, only exhibiting loss of DA or DA terminals. The
reason for this remarkable resistance of DA neurons to
the toxicity of transgenic !-synuclein is unclear. Viral
models have been more successful in reproducing the
specific DA neuron death that is characteristic of PD.
Although the results from the !-synuclein transgenic
mice are highly variable, it is instructive to consider the
factors behind this variability. These differences might
be explained by the amount of !-synuclein expression
attained in each model, the location of gene expression in
the brain, and the duration of the experiment. Another
important caveat is that endogenous !-synucleinmight
interfere with Lewy body formation. The combination
ofmouse and human !-synuclein prevents !-synuclein
fibril formation,owing to an inhibitory substitution at
asparagine 87 (REFS 24,88,90). Rat !-synuclein, which 
contains a threonine at position 53,might also interfere
with toxicity after overexpression of human A53T 
!-synuclein. To circumvent this problem,!-synuclein-
knockout mice could be used in combination with viral
overexpression of human !-synuclein. These knockouts
are viable, can breed, and have normal DA neuron 
function35. It is therefore possible that they could be
transduced with human !-synuclein.
Animal models of the synucleinopathies are essential
for the study of both idiopathic and hereditary PD,
diseases that are characterized by the presence of wild-
type or mutant (A30P and A53T) !-synuclein, respec-
tively. Future development of these models should focus
on using viral expression systems to transduce rodents
and primates with the !-synuclein gene. Specifically, the
Conclusions
Alth ugh no animal model of the synucleinopathies
shows the complete spectrum of PD features, the models
described in this review complement each other and
have helped elucidate various elements of disease patho-
genesis. Animal models of the synucleinopathies were
created using neurotoxins that inhibit complex I (MPTP
or rotenone),o  by overexpressing !-synuclein (FIG. 4). In
both cases,!-synuclein accumulates in neurons, leading
to the formation of protofibrils, fibrils and occasional
Lewy body-like inclusions.
There are marked differences between the intoxica-
tion and genetic !-synuclein models with regard to
selective DA neuron loss,presence ofmotor deficits and
Lewy b dy development (TABLE 2). The intoxication
MPTP
Rotenone
Wild-type !-synuclein
overexpression
A30P/A53T !-synuclein
overexpression
Complex 1
inhibition
Mitochondrion
ROS
Dopamine neuron death Cell survival
Lewy body-like
inclusions 
!-Synuclein
ol gomers
!-Synuclein
fibrils
!-Synuclein
monomers
Apoptosis
Cytotoxicity
+ +
?
?
Figure 4 | Generation of animal models of the synucleinopathies. Animal models of the
synucleinopathies have been created using neurotoxins (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or rotenone) or by overexpressing !-synuclein. In both cases, 
!-synuclein accumulates in the cells, leading to formation of protofibrils, fibrils, and occasional
inclusion bodies. Overexpression of A30P or A53T !-synuclein results in an increased
concentration of !-synuclein oligomers. Overexpression of wild-type !-synuclein leads to an
increased concentration of !-synuclein monomers, which then undergo oligomerization and form
fibrils. When inhibitors of mitochondrial complex I such as MPTP and rotenone are used, radical
oxidative species (ROS) are formed, and apoptotic or cytotoxic cascades are activated, ultimately
leading to death of dopamine neurons. The ROS also induce !-synuclein aggregation and
protofibril formation29,30. The protofibrils can then lead to further ROS production31,32, generating 
a feedforward process that could potentiate neuronal degeneration.
Table 2 | I toxication and genetic models of synucleinopathies
Characteristics of PD Intoxication models !-Synuclein genetic models
MPTP-treated Rotenone-treated Drosophila Rodents Primates
DA neuron loss + + + variable +
Motor deficits + + + + variable
Lewy bodi s Intracytoplasmic + + variable Intracytoplasmic
granular inclusions granular inclusions
Time of onset Immediate Immediate Advanced age Advanced age Immediate
(transgenics); (viral vectors)
immediate 
(viral vectors)
Complex I inhibition + + ? ? ?
DA, dopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson’s disease. 
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Table 1: Examples of neurological diseases where aberrant protein aggregates are found, and the suggested conformations in the aberrant
aggregates are indicated.
Proteinopathies (aberrant aggregation)
Disease Protein Pathological finding Protein conformation
Prion diseases PrPSc PrP amyloid plaques β-sheet
Alzheimer’s disease
Aβ Aβ amyloid plaques β-sheet
Tau
Paired helical filaments
β-sheet + α-helix
in neurofibrillary tangles
Parkinson’s disease α-synuclein Lewy bodies β-sheet + α-helix
Frontotemporal dementia Tau
Straight filaments
—–
and paired helical filaments
Pick’s disease Tau Pick bodies —–
Progressive supranuclear palsy Tau Straight filaments is neurfibrillary tangles —–
Amyotrophic lateral sclerosis Neurofilament Neural aggregates —–
Huntington’s disease Huntingtin Nuclear inclusions β-sheet
Spinocerebellar ataxia
Type 1 Ataxin 1 Nuclear inclusions β-sheet
Type 2 Ataxin 2 Cytoplasmic inclusions β-sheet
Machado-Joseph disease Ataxin 3 Nuclear inclusions β-sheet
been indicated for other proteins related to neurodegener-
ative disorders [14], where a TATA binding protein may play
a role. Tau degradation may take place through the protea-
some complex [15, 16] and it has been suggested that such
degradation could be regulated by posttranslational modifi-
cations occurring in tau molecule, like its phosphorylation
[17]. Also, tau degradation by other proteases could be reg-
ulated by its level of phosphorylation [18]. It should be also
indicated that in some cases like Parkinson’s disease or Lafora
disease, mutations in the E3 ubiquitin ligases like parkin [19]
or malin [20] will result in the appearance of aberrant pro-
tein aggregates.
A conformational change, that could be followed by anti-
bodies that react with tau molecule after that conformational
change [21–24] has been also suggested to be required for the
transition tau monomer-tau polymer.
Also, it has been suggested that different posttranslational
modifications like phosphorylation [25], glycation [26], or
truncation [27], may play a role in the formation of tau poly-
mers.
Due to the alternative splicing of its heterogenous (or nu-
clear) RNA, different tau isoforms could be expressed and,
therefore, different tau aggregates with different tau isoforms
in different tauopathies could occur, but we will not discuss
this point here. For further information see [8].
Mainly, studies on phosphorylation and truncation have
been done. About truncation, it has been suggested that re-
moval of the amino and/or carboxy terminal regions, leaving
the tubulin binding region will facilitate tau polymerization
[21, 22, 28].
Some work has been done in vitro [29] and in vivo
[30, 31] about a possible role of tau phosphorylation on tau
assembly, suggesting that in some conditions tau phosphory-
lation may increase the capacity of tau for its self-assembly.
Not only an increase in serine/threonine phosphorylation of
tau could regulate its aggregation but also an increase in tau
tyrosine phosphorylation may increase the formation of tau
aggregates [32]. This assembly process may involve the for-
mation of oligomers [33], filaments, and aggregates of fila-
ments (tangle-like structures). In the formation of these ag-
gregates of filaments, glycation may play a role [26].
The possible relation between phosphorylation and tau
aggregation has been studied in transgenic mice express-
ing human tau bearing some mutations found in human
fronto-temporal dementia linked to chromosome 17 (FTDP-
17) [31]. In this mouse, tau phosphorylation mainly oc-
curs by GSK3 [34]. When a specific inhibitor of this kinase,
lithium, was given to the transgenic mice no tau phosphory-
lation was found, and in addition no aggregation of the pro-
tein was detected [31] suggesting a correlation between tau
phosphorylation and aggregation in this model. This result
was supported by an additional experiment using another
mouse also expressing human tau with a FTDP-17 mutation
[30].
Alternatively, protein chaperones, acting on tau or in
phosphotau, could modify the level of tau aggregation, ex-
amples could be the protein 14-3-3 [35], musashi-1 [36],
or Pin-1 [37, 38]. The chaperone associated ubiquitin ligase
CHIP could be able to target phosphotau for proteasomal
degradation [16, 18].
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!-pleated sheet structure in the tau lesions of severe AD brain,
immunofluorescent labeling was performed using Tau-nY29 to-
gether with Thiazin Red (Mena et al., 1995). Laser scanning con-
focal microscopy demonstrates that Tau-nY29 recognizes only a
subset of Thiazin Red-positive NFTs (Fig. 7A–C). For example,
numerous NFTs that stain intensely with Thiazin Red show little
to no staining with Tau-nY29 (Fig. 7A–C, arrowhead). In con-
trast, very few, if any, tangles stained with Tau-nY29 alone.
Whereas Thiazin Red highlights the dystrophic neurites present
within neuritic plaques, Tau-nY29 fails to strongly detect these
structures (Fig. 7A–C, arrow).
To define whether the Tau-nY29 epitope colocalizes with
markers of early stage tau pathology, we also performed double-
label studies in which Tau-nY29 was paired with the antibody
Alz-50. Alz-50 is a conformation-dependent probe that recog-
nizes early filamentous changes in tau (Hyman et al., 1988; Car-
mel et al., 1996). Qualitatively, we found that the Tau-nY29 and
Alz-50 antibodies colocalize to an appreciable extent in the NFTs
of severe AD cases. In double-labeled, tangle-bearing neurons,
intense colabeling was also observed in the proximal dendritic
arborizations (Fig. 7F, arrow).Double-labeling experimentswere
also performed on sections of PiD brains. In these cases, Tau-
nY29 and Alz-50 staining cosegregated in most, but not all, Pick
body inclusions. Interestingly, the majority of double-labeled
Pick bodies exhibit a chimeric pattern whereby Tau-nY29 stain-
ing occupies a central region, and Alz-50 decorates the periphery
of the inclusion (Fig. 7G–I, arrow). Because of the marked coseg-
regation of Tau-nY29 and Alz-50 in these cases, our findings
suggest that tau nitration at Tyr29may occur in the early stages of
diverse tauopathies (see Discussion).
Discussion
Tau-nY29 is a novel nitro-tau-specific mAb
Multiple lines of evidence suggest that tau nitration plays amech-
anistic role in the pathogenesis of diverse tauopathies. Until re-
cently, much of our understanding of tau nitration in vivo origi-
nated from studies using the n847 antibody (Horiguchi et al.,
2003). It should be noted, however, that although n847 has been
considered a reliable marker of tau nitration, it demonstrates
specificity only for 3-nitrotyrosine. The n847 antibody is neither
protein specific nor dependent on the amino acid sequence sur-
rounding any given Tyr residue. In support of this, Horiguchi et
Figure 6. Tau-nY29 differentially labels the fibrillar tau inclusions of non-AD tauopathies. In PiD cases, Tau-nY29 stains numerous Pick body inclusions in the frontal cortex (A) and granular cell
layer of the dentate gyrus (B). C, Ramified astroglia (arrow) also exhibit robust labeling with Tau-nY29. D, The AD2 antibody, which serves as a positive control for tau pathology in the non-AD
tauopathies, labels both the ramifiedastroglia (arrow)andPickbodies (asterisk).E,F, InPSP, Tau-nY29detectsgloboseNFTs in the frontal cortex.Notably, theglial pathologyofPSP, including thorny
astroglia (G), tufted astroglia (H, arrow), and coiled bodies (H, asterisk), lacks Tau-nY29 reactivity. Moreover, Tau-nY29 exhibits little-to-no staining of neuritic threads (G, arrow) in the graymatter
of the frontal cortex. Theperinuclear inclusionsof CBDarehighly reactive towardboth theTau-nY29 (I, asterisk) andAD2 (J, asterisk) antibodies.However, theneuritic thread-likeprocesses (J, arrow)
and astroglial plaques within the frontal cortex (K ) lack significant Tau-nY29 staining. L, Dense Tau-nY29-positive threads (arrow) were observed in the pons of CBD cases. Scale bar, 25"m.
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Mechanisms of aggregate uptake. In cultured 
cells, internalized α-synuclein aggregates 
partially co-localized with endosomal  
and lysosomal markers35. Expression of  
a dominan t-negative form of dynamin — a 
GTPase required for endocytic membrane 
fusion — inhibited this uptake. This implies 
that the endocytic machinery is involved 
in this process35 (FIG. 2b). Amyloid fibrils, 
including those associated with systemic 
amyloid disease48 and those not normally 
found in eukaryotes49, can be internalized 
by cultured cells, possibly by breaching the 
plasma membrane (FIG. 2b). Although these 
findings raise the possibility that mam-
malian cells might have a greater ability 
to internalize ordered fibrillar aggregates 
than previously thought, further studies 
are required to understand the molecular 
mechanisms.
Even if neurons and other mammalian 
cells take up fibrillar aggregates by endo-
cytosis, in order for them to nucleate 
aggregation of endogenous cytoplasmic 
proteins, which is essential for the ‘prion-like’ 
hypothesis, they must escape the intracellular 
vesicle and gain access to the cytoplasm. The 
aggregates investigated in the cell culture 
studies described above are too polar to dif-
fuse passively across lipid bilayers and too 
large to pass through transmembrane pores 
or transporters. Nonetheless, extracellular 
aggregates containing polyglutamine42, tau39 
and α-synuclein34 have now been shown to 
enter cells and cause seeding of endogenous 
proteins. Deep-etch electron microscope 
images of polyglutamine aggregates shortly 
after internalization into cultured cells 
revealed ‘naked’ aggregates on the cyto-
plasmic face of the plasma membrane. There 
was no evidence of a surrounding membra-
nous structure42, suggesting that aggregates 
can penetrate the plasma membrane in the 
absence of vesicular uptake. Studies in artifi-
cial systems on α-synuclein oligomers show 
that they can render lipid bilayer membranes 
permeable to fluorescent dyes, suggesting 
that α-synuclein aggregates can intercalate 
directly into lipid membranes50. This pro-
vides a potential means by which aggregates 
could exit from endosomes or perhaps cross 
the plasma membrane directly. Finally,  
it is possible that tunnelling nanotubes — 
50–200 nm diameter actin-rich hollow  
filaments seen between interconnected cells 
in culture51 — can act as transport conduits 
for prion-like protein aggregates, as has been 
suggested for PrP51 (FIG. 2c).
Conclusions and perspectives
Several neurodegenerative diseases have 
symptomatic onset in mid or late life and 
often have protracted courses. This is 
evident in dominantly inherited familial 
diseases such as Huntington’s disease and 
rare familial forms of Alzheimer’s disease 
and Parkinson’s disease, in which the central 
nervous system copes with the continued 
synthesis of mutant, aggregation-prone 
proteins for many decades before eventu-
ally exhibiting neuropathology. Cellular 
defences, such as those described in BOX 2, 
probably suppress the formation of aggre-
gation nuclei during this latent period. In 
these diseases, as with the more common 
Figure 3 | Principles for progression of neuropathological changes. a | Intracellular protein aggre-
gates can be released from neurons by exocytosis or cell death. The aggr gates ar  taken up by, for 
example, adjacent neuronal cell bodies and are either retained in the cell soma (local spread of path-
ology) or transported anterogradely by axons. Alternatively, they are taken up by axon terminals and 
transported retrogradely to the cell soma. The protein aggregates can spread between brain regions 
by axonal transport. b–d | Three drawings propose principles for how neuropathological changes in 
Parkinson’s, Alzheimer’s and Huntington’s diseases spread spatiotemporally during disease progres-
sion. The earlier the neuropathology develops in a given brain region, the darker the shading in the 
diagram. As only one view (mid-sagittal for Parkinson’s and Alzheimer’s diseases; lateral for Huntington’s 
disease) of the brain is depicted for each disorder, not all relevant anatomical structures and details of 
the spreading patterns (indicated by arrows) are presented. b | In Parkinson’s disease, α-synuclein 
aggregates (Lewy neurites and Lewy bodies) are suggested to first appear in the dorsal motor nucleus 
of the vagal nerve in the brainstem and anterior olfactory structures (darkest green), and then to spread 
stereotypically to finally occupy large parts of the brain4,5. c | In Alzheimer’s disease, neurofibrillary tan-
gles first appear in the hippocampus (and closely associated structures), the basal nucleus of Meynert 
and the brainstem15–18 (darkest green). They spread to other brain regions, including the neocortex, in a 
stereotypical manner, correlating with symptomatic progression. d | In Huntington’s disease, the puta-
men and caudate nucleus, and related basal ganglia structures deep inside the brain (darkest green), 
have been suggested to degenerate first25–27. However, recent imaging studies suggest that primary 
motor and sensory cortices already undergo atrophy in pre-symptomatic gene carriers28. Therefore 
we propose that cortical involvement precedes basal ganglia pathology.
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Because of their constant subnanometric width and their
capacity to reach lengths of several mm, WT and RETRO (and
cysteine-terminated C-WT and C-RETRO) protofibrils are
a potentially useful platform for the development of nanowire
elements. However, for nanotechnological purposes, the control
of the orientation of the nanowires can be as important as the
control of the nanowire fabrication itself. The ability of graphite
to induce the orientation of peptide fibrils has been previously
observed,102,103 and we have shown that it is a very effective
template to align WT and RETRO protofibrils along the three
characteristic directions of its hexagonal lattice, an effect that
could be potentiated by the preadsorption of DMSO on the
graphite surface.
Conclusions
The spontaneous self-assembly into thin, straight and very long
protofibrils suggests that WT and RETRO can be interesting
candidates as templates for nanowire fabrication. Substrates like
graphite or DMSO-coated graphite are able to orientate those
thin fibrillar assemblies along well-defined parallel or 60/120
degree directions. Easy peptide assembly and effective control of
the directions of the deposited fibrillar structures are a very
attractive combination for the development of new amyloid-
based nanotechnological systems.
The growth of amylin-derived peptide protofibrils at physio-
logical ionic strength and neutral pH suggests that they can be
used in vivo as template structures with potential biomedical
applications ranging from nerve cell growth guidance to bone
healing and reconstruction. Ironically, naturally occurring
amyloid fibrils associated with some of the most devastating
diseases could provide new materials for technologies that can be
applied to the improvement of human health.
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WT, side view. (c) RETRO, front view. (d) RETRO, side view. Yellow arrows show b structure, pointing fromN-terminal to C-terminal. Atom colours:
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cross-b regions are much more abundant in bacterial
aggregates. This composition, together with their high
protein density (1.3 mg/ml) [18], could prevent the obser-
vation of fibrillar structure in IBs. Fortunately, it is
possible to discriminate between fibrillar and non-fibrillar
regions in protein aggregates. Proteinase K (PK) has been
extensively used to map the core of amyloid fibrils because
it is highly active against globular or disordered confor-
mations but displays low activity against densely packed
cross-b regions [19]. Interestingly, PK treatment of the
apparently amorphous bacterial IBs formed by the Alzhei-
mer’s disease (AD) amyloid b (Ab) peptide promotes the
appearance of elongated fibrillar structures with heights
ranging from 2 to 5 nm, which is consistent with the
dimensions and morphology of amyloid protofilaments
and fibrils as observed both by EM and AFM (Figure 1).
Accordingly, PK-digested material binds Th-T and congo
red with higher affinity than intact IBs [7].
The presence of a structured core in a protein
aggregate can also be mapped by measuring quenched
Figure 1. Amyloid properties of bacterial IBs. The biophysical and structural characterization of the IBs formed by unrelated proteins demonstrates that these insoluble
deposits contain amyloid-like structures. b-Sheet secondary structures in IBs: (a) X-ray diffraction of early secreted antigen 6-kDa protein (ESAT-6) IBs, showing the two
typical reflections at 4.7 A˚ and !10 A˚ consistent with a cross-b structure; (b) far-UV CD spectra of ESAT-6 IBs, displaying the characteristic minimum at around 217 nm
indicative of a b-sheet conformation; (c) Fourier transform infrared spectroscopy (FTIR) spectrum of the IBs formed by two fusions of b-galactosidase and the capsid protein
of foot-and-mouth disease virus (VP1LAC, red, and LACVP1, blue) and the tailspike protein (TSP, green), with two bands at 1621 cm"1 and 1691 cm"1 characteristic of a
intermolecular b-sheet structure; the band at 1651 cm"1 indicates the presence of disordered conformations.Binding of IBs to amyloid-specific dyes: (d) increase in the
fluorescence emission of Th-T in the presence of different IBs (VP1LAC in green, LACVP1 in red and TSP in blue) compared with that promoted by soluble conformations
(VP1LAC in black); (e) shift in the absorption spectra of congo red in the presence of different IBs (VP1LAC in green, LACVP1 in red and TSP in blue) compared with that
promoted by soluble conformations (VP1LAC in black); (f) congo red birefringence of the IBs formed by myelin oligodendrocyte glycoprotein (MOG) under cross-polarized
light. Amyloid-like fibrils in IBs imaged by transmission electron microscopy (TEM) and atomic force microscopy (AFM): (g) TEM image of bone morphogenetic protein-2
IBs after in vitro incubation at 37 8C for 12 h; (h) TEM image of Ab IBs after 30 min of PK proteolytic action; (i) AFM image of IBs (Ab–GFP) digested for 30 min with PK; fibril-
like structures settling on the graphite surface are indicated with white arrows. Seeding-dependent formation of amyloid fibrils: (j) the formation of Ab fibrils is accelerated
by the addition of preformed fibrils (red line) and Ab IBs (green line) in comparison to the spontaneous aggregation of monomeric Ab (blue line). (a), (b), (f) and (g) adapted,
with permission, from Ref. [8]; (c), (d) and (e) adapted, with permission, from Ref. [5]; and (h), (i) and (j) adapted, with permission, from Ref. [7].
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The next point that we must to clarify is which kind of amyloid
species is inserted in the bilayer. Although different amyloid
species, like oligomers, may contribute to amyloid toxicity and
could be related to membrane poration and disruption [58] several
studies point to tetramers and hexamers bound to membrane as
the main responsibles of membrane poration and subsequent
disruption [36]. As showed in Table 1, while kn is clearly affected by
liposomes and their net charge, ke is practically unaltered by the
presence of liposomes. This suggests that the mechanism behind
the observed increase in lag time must originate from interferences
taking place during the build up of small oligomers from mono-
mers. This implies that are the soluble Ab40, and not the mature
ﬁbrils, the species that interact with membranes. Also, the
permeability studies (Fig. 5) allow us to afﬁrm that the ﬁrst
membrane disruption events occur before amyloid aggregation can
be observed, suggesting that membrane disruption could be due to
the binding of initially soluble Ab40 species, without a requirement
for the formation of structured species. Determination of CL release
shows a clear acceleration of membrane disruption in presence of
charged liposomes, inwhich a higher concentration of Ab peptide is
expected to be ﬁxed to the membrane.
The association of soluble Ab peptide to the bilayer is also
modulated by the colloidal characteristics of the peptide, which
forms micelles at concentrations above 17.5 mM (the corresponding
critical micellar concentration (cmc)) [59e61]. Such micelles can
act as a reservoir of soluble material available for subsequent
ﬁbrillogenesis. It should be noted that, at peptide concentrations
above the cmc, the lag time of the reaction remains essentially
constant, but at peptide concentrations below 17.5 mM, the lag time
correlates with the peptide concentration. The association
(adsorption and/or insertion) of the Ab40 to membranes may to
reduce the effective concentration of soluble Ab40 peptide in the
solution, and, in such circumstances, the peptide concentration
might become below the cmc, with a concomitant reduction in the
nucleation rate of the reaction.
Other important ﬁnding derived from our study is the obser-
vation that the interaction of the peptide with liposomes results in
an increase in the b-sheet content of the peptide. It is known from
CD measurements that Ab peptide has mainly random-coil
secondary structure in solution, while it adopts b-sheet confor-
mation oriented almost parallel to the monolayer surface in the
adsorbed state [22,23]. The increase in b-sheet conformation in the
presence of liposomes could be caused either by the adsorption of
peptide on the external monolayer of liposomes, in which well-
formed ﬁbrils could grow, or by the nucleation delay that favours
better peptide accommodation and well-formed amyloid ﬁbrils.
Factors that delay the nucleation process tend to increase the levels
of b-sheet in unrelated amyloidogenic polypeptide systems. For
instance, the inﬂuence of temperature on the nucleation rates
correlates well with changes in the morphology of the ﬁbrils
formed by barstar, insulin, a-synuclein and HET-s (218e289)
[62e65]. Also, for the PI3-SH3 domain, pH values promoting fast
aggregation reactions were shown to cause disorganized ﬁbrillar
structures, whereas pH values allowing slow polymerization led to
well-ordered ﬁbrils [66]. The interaction of the b-peptide with
neutral liposomes illustrate how the increase in the lag time results
in amyloid species displaying higher inter-molecular b-sheets,
whereas with negatively charged liposomes both scenarios
(adsorption on the liposome and delay in the ﬁbrillation rate) might
contribute to increase in b-sheet conformation with negatively
charged with.
Dye-binding assays have shown that the presence of liposomes
reduces the concentration of ﬁbrils. This is in agreement with an
insertion of Ab40 peptides into themembrane, since it would result
in a reduction in the amount of soluble Ab40 available to form
amyloid ﬁbrils. Interestingly enough, a direct relationship between
the amount of amyloid-like aggregates and the negative charge
increment can be observed. This is likely due to the fact that in
neutral liposomes most of the membrane-associated peptide is
hidden inside the liposome core and therefore not available for
amyloid formation, whereas in negative liposomes, the peptide
associated to the membrane is prone to undergo a conversion into
amyloid structures. Since ﬁbril concentration can be directly related
to the amount of available soluble peptide [60], more amyloid ﬁbril
mass is expected when the aggregation is carried out without
liposomes, a condition in which all soluble species are available for
taking part in the polymerization reaction. As observed by TEM, the
peptideephospholipid interaction leads to a dramatic alteration in
size and shape of ﬁbrils. Long amyloid ﬁbrils are observed in
absence or presence of neutral liposomes. A reduction in ﬁbril size
is observed in presence of negatively charged liposomes. As noted
above, in absence and in presence of neutral liposomes only the
soluble species present in the bulk solution participate in amyloid
polymerization, whereas extended peptides ﬁxed in the liposome
surface participate in the elongation process in presence of charged
liposomes. Our data demonstrates that the way Ab40 interacts with
Fig. 6. Schematic model for the interaction of Ab40 with liposomes. Top: neutral
liposomes (the peptide is anchored in the membrane). Bottom: Negatively charged
liposomes (the peptide is anchored in the membrane but it is also adsorbed by elec-
trostatic forces on the external monolayer of the liposome).
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productive collisions betweenmonomers. These two
effects would result in faster nucleation reactions.16
This mechanism might explain why DESIGN, in
which amyloidogenic residues are more scattered
throughout the sequence than in the WT and
RETRO sequences, displays the longest lag phase
and the lowest elongation rate among the analyzed
IAPP peptides. The slow a gregation process of the
DESIGN peptide is captured by the different
prediction algorithms used in the present study,
which in all cas s predict aggregation propensities
below the respective thresholds and indicate that the
programs are sensi iv to fibril formation rates.
Nevertheless, DESIGN does finally slowly self-
assemble into amyloid-like conformations. This
indicates that even when the aggregation propensity
of polypeptid is intrinsically low, it might still
expl re conformation l landscapes, leading to self-
assembly into stable macromolecular structures.
The elo ti n of DESIGN fibrils differs signifi-
cantly from theWT sequence in terms of energy. The
low-energy barrie to th WT sequence indicates a
facilitated diffusion-controlled growth process. This
is in contrast to the high- nergy barriers exhibited by
DESIGN, which suggests that the monomer requires
a chemical transformation before it can be accom-
modated at the growing fibril ends. The entropic and
enthalpic contributions to the elongation reactions
are also significantly different. In WT, two cooper-
ative effects of similar magnitude appear to control
fibril formation, as the reaction is unfavorable from
both enthalpic and entropic points of view. In
contrast, the free energy of elongation for DESIGN
results from the difference between a larger activa-
tion energy and a favorable entropic contribution. In
this case, the activated and inactive states signifi-
cantly differ in energy. The different aggregation
landscapes explored by the WT and DESIGN
peptides, which share a common amino acid
composition, result in the formation of macromolec-
ular structures that differ in secondary structure
content, stability, dye binding properties, and
toxicity. These differences provide further support
to the view that the distribution of side chains in the
sequence, as it occurs in protein folding, plays a
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Fig. 8. Seeding and cross-seeding kinetics of WT (a),
RETRO (b), and DESIGN (c) peptides in the presence of
10% of preformed WT, RETRO, and DESIGN fibrils. The
fibrillar fraction of peptides is represented as a function of
time. Note that, in all cases, the formation of amyloid
fibrils is accelerated only by the addition of homologous
preformed fibrils. The aggregation reactions have been
performed at 25, 37, and 49 °C for WT, RETRO, and
DESIGN peptides, respectively, with agitation.
Fig. 9. Viability analysis of SH-SY5Y cells exposed to
WT, RETRO, and DESIGN amyloid fibrils for 48 h. Error
bars indicate ± SE (n=6). One hundred percent cell
viabil ty was assigne to control samples corresponding
to cells incubated in peptide free DMEM.
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AβMRF causes nonsense suppression in yeastFigure 1
AβMRF causes nonsense suppression in yeast. (Upper panel) Schematic illustration of the constructs used in this study: 
(a) full length Sup35p (NMRF) (b) Sup35p without the N-terminal prion domain (MRF) (c) Aβ42 fused to the N terminus of 
MRF (AβMRF) (d) AβMRF carrying a double mutation of Phe19,20Thr in its Aβ42 portion (Aβm1MRF) (e) AβMRF carrying a 
triple mutation of Phe19,20Thr and Ile31Pro in its Aβ42 portion (Aβm2MRF). All these constructs carry an HA tag between the 
M and RF domains. Images shown are not to scale. (Lower panel) Equal numbers of ade1-14 cells containing a genomic deletion 
of SUP35 (sup35∆), and carrying the indicated constructs (a-e) on a plasmid were grown on complex medium, or synthetic 
medium supplemented (+Ade) or not (-Ade) with adenine. (a) Cells with inactivated NMRF ([PSI+]) had an impaired transla-
tional termination activity, were white and grew on -Ade. (b) Cells with fully active MRF (lacking the aggregation-prone prion, 
N, domain), were red and failed to grow on -Ade. (c) Cells expressing AβMRF have an impaired translational termination activ-
ity, as they were white and grew on -Ade. (d, e) The translational termination activity was restored by F19,20T (Aβm1MRF) 
and F19,20T/I31P (Aβm2MRF) mutations in the Aβ42 region of the fusion protein, making the cells dark pink and preventing 
their growth on -Ade.
!"#$!%&'&()!"##$%!!&'" ())*&++,,,-./0123425)678-401+9:;9<:##:+;+'"
=7>2!'!0?!9"
*+,(-$./01-2$.&3$4&2$5%3,3%&.$+/2+&6-67
AβMRF causes nonsense suppression in yeastFigure 1
AβMRF causes nonsense suppression in yeast. (Upper panel) Schematic illustration of the constructs used in this study: 
(a) full length Sup35p (NMRF) (b) Sup35p without the N-terminal prion domain (MRF) (c) Aβ42 fused to the N terminus of 
MRF (AβMRF) (d) AβMRF carrying a double mutation of Phe19,20Thr in its Aβ42 portion (Aβm1MRF) (e) AβMRF carrying a 
triple mutation of Phe19,20Thr and Ile31Pro in its Aβ42 portion (Aβm2MRF). All these constructs carry an HA tag between the 
M and RF domains. Images shown are not to scale. (Lower panel) Equal numbers of ade1-14 cells containing a genomic deletion 
of SUP35 (sup35∆), and carrying the indicated constructs (a-e) on a plasmid were grown on complex medium, or synthetic 
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PERSPECTIVES
What Makes a Prion Infectious?
BIOCHEMISTRY
Surachai Supattapone
Nonproteinaceous cofactors may be essential to 
generate infectious prions.
 P
rions are unconventional infectious 
agents that cause fatal neurological 
illnesses such as Creutzfeldt-Jakob 
disease, bovine spongiform encephalopa-
thy, and scrapie. Many hypotheses have been 
advanced to explain the chemical composi-
tion of infectious prions and the mechanism 
of their formation in the neurons of infected 
hosts, but none has yet been proven. Per-
haps the most provocative proposal has been 
the “protein-only” hypothesis, which posits 
that the infectious agent is composed exclu-
sively of a misfolded, host-encoded protein 
called the prion protein (PrP). However, three 
decades of investigation have yielded no 
direct experimental proof for this stringent 
hypothesis. Moreover, various biochemical 
studies have suggested that nonproteinaceous 
cofactors may be required to produce infec-
tious prions, possibly by forming physical 
complexes with PrP ( 1– 4). On page 1132 of 
this issue, Wang et al. demonstrate the impor-
tance of cofactors for producing recombinant 
infectious prions in vitro ( 5). Another study 
by Li et al. suggests that endogenous cofac-
tors may also infl uence the strain properties 
of prions in cells ( 6).
Misfolded PrP that is associated with dis-
ease can convert normal PrP into an aberrant 
form. In a subset of cases, aggregates of mis-
folded PrP form amyloid fi bers, which can 
accumulate and form plaques in the brain. A 
central prediction of the protein-only hypoth-
esis is that it should be possible to generate 
prions with high specifi c infectivity by chem-
ically refolding PrP in vitro in the absence 
of other cellular components. The specifi c 
infectivity of an infectious agent is mea-
sured by an end-point titration bioassay of a 
known quantity of the agent in susceptible, 
wild-type hosts. Previous studies have shown 
that using chemical denaturants to fold puri-
fi ed recombinant PrP (produced by geneti-
cally engineered bacteria) into amyloid fi brils 
yields products with minimal infectivity ( 7, 
 8). Although end-point titration was not per-
formed in these studies, extremely low spe-
cifi c infectivity may be inferred because wild-
type rodents failed to develop clinical disease 
when inoculated with samples of highly con-
centrated protein.
By contrast, a mixture of native PrP and 
lipid molecules purified from noninfected 
hamster brain, plus synthetic polyadenylic 
acid RNA molecules, resulted in the de novo 
formation of prions whose specifi c infectivity 
was comparable to that of naturally occurring 
prions ( 3). Although these results indicated 
that nonproteinaceous cofactors were neces-
sary for generating native prions, it remained 
unknown whether the addition of such cofac-
tors could facilitate the production of infec-
tious prions from recombinant PrP ( 9).
 In a major advance, Wang et al. report that 
mixing recombinant PrP with total liver RNA 
and synthetic 1-palmitoyl-2-oleoyl-phosphati-
dylglycerol (POPG) lipid molecules produces 
bona fi de infectious prions ( 5). Building upon 
their earlier work showing that POPG pro-
motes the conversion of PrP into an aberrant, 
protease-resistant conformation ( 2), Wang et 
al. used the protein misfolding cyclic ampli-
fi cation technique ( 10) to generate recombi-
nant prions de novo. Remarkably, the resulting 
recombinant prions were infectious to wild-
type mice and displayed unique strain char-
acteristics (prion strains are self-propagating 
variants with distinct PrP conformations and 
infectious phenotypes). Although an end-
point titration bioassay was not performed, a 
100% fatality rate among inoculated animals 
and a short incubation period between inocu-
lation and disease onset suggest high specifi c 
infectivity. The contrast between the bioas-
say results obtained with recombinant prions 
formed with lipid and polyanionic cofactors 
and those obtained using recombinant PrP 
Department of Biochemistry, Dartmouth Medical School, 
Hanover, NH 03755, USA. E-mail: supattapone@dartmouth. 
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Bacterially expressed 
recombinant PrP
Minimal infectivity
Amyloid fibrils
Protein 
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Extra ingredients. Two different biochemical protocols yield recombinant PrP with different infectivity. (Left) 
Minimally infectious amyloid fi brils are formed by incubating recombinant PrP with chemical denaturants. 
(Right) Mixing recombinant PrP with phospholipid and RNA produces highly infectious prions.
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